Figure 6 –

Zafirlukast inhibits CA-125 doubling time. The rate of CA-125 doubling time (A) prior to and (B) after zafirlukast treatment. The mean change in CA-125 was 0.036 U/mL per day prior to treatment compared with 0.015 U/mL per day following zafirlukast (paired t-test p=0.026) (C) Comparison of the average pre and post treatment doubling times of CA-125. (D) The relative thiol isomerase activity of each patient 28 days after treatment, the reduction of which was well correlated (E) to the decrease in CA-125 doubling time.